Orikine Bio — Seed (estimated) · €2.7M

Orikine Bio raised €2.7M in a syndicated investment from CDTI Innovación's SICC Innvierte, alongside its existing investors Sabadell Asabys (Health Innovation Investments II FCR and 2B SCR) and AdBio Partners (AFB Seed Fund II). The money funds its Foldikine bispecific-cytokine therapies for autoimmune, inflammatory and oncological diseases. The sources give no stage, so it is filed as a seed extension, and they name no lead. The company separately received a €335k NEOTEC 2024 grant from CDTI.